Our partners

For over 20 years, EDCTP has brought together African and European partners to advance health research through coordinated action, shared priorities and pooled resources, enabling progress that would not be possible individually. 

Global Health EDCTP3 collaborates with a wide range of public and private partners to foster greater collaboration in global health. This includes pharmaceutical companies, Product Development Partnerships (PDPs), international organisations, research institutions, regulatory authorities, civil society organisations and philanthropic organisations, among others.

We structure our partnerships in three categories: 

• Contributing partners: Any private entity, or a public organisation from countries outside the EDCTP Association, that co-funds and often implements projects. 
• Other co-funders: Public entities based in EDCTP Association member countries whose contributions support specific projects and are treated as equivalent to those made directly by the EDCTP Association member countries. 
• Strategic partners: Organisations that collaborate with us on a broader set of activities that extend beyond mere co-funding or project implementation and help advance and align our shared strategic goals. 

Data: September 2026 

60 contributing partners have committed over €176 million in co-investments. Of those, 30 organisations are registered in Africa (50%) and 26 in Europe (43%), with the remaining six based in the USA and China.

A further €92 million has been pledged by aspirant contributing partners supporting project proposals currently under review.

Contributions to the call for proposals

Of the committed amount, €49.4 million has been mobilised through calls for proposals developed jointly with five contributing partners:  

• Novo Nordisk Foundation (NNF): €18 million 
• Gates Foundation: €15.5 million 
• Coalition for Epidemic Preparedness Innovations (CEPI): €14.5 million 
• BioNTech: €1 million 
• Leprosy Research Initiative (LRI): €0.4 million 

In addition to providing resources, these contributing partners bring valuable scientific expertise that helps shape our calls for proposals in line with the latest research and portfolio developments, while promoting alignment with their own investments and initiatives.

Contributions at project level

Contributing partners can also provide funding and expertise to support specific projects, with their contributions scored as part of the evaluation of their applications.  

Notable project-level contributing partners include: 

• Tuberculosis vaccines: IAVI, Biofabri, Uganda National Health Research Organisation (UNHRO), Afrigen, and Access to Advanced Health. 
• Next-generation antimalarial medicines: Novartis, GSK, the Centre de Recherches Médicales de Lambaréné (CERMEL) and Medicines for Malaria Venture (MMV). 
• Networks of excellence and epidemic preparedness: the University of Global Health Equity, CTI, Africa CDC, the Ifakara Health Institute and the INDEPTH Network, supporting our five networks of excellence that bring together more than 100 institutions to strengthen clinical and epidemiological research capacity. 
• Treatments and vaccines for viral and parasitic diseases: Laboratorios Liconsa, the Mundo Sano Foundation and Valneva.

Data: September 2026 

These organisations are public entities based in EDCTP Association member countries (including public health agencies, universities and national research centres) that also provide co-funding contributions supporting specific projects. 

Member countries of the EDCTP Association are part of the Global Health EDCTP3 governance structure and declare their planned annual co-funding contributions when preparing annual work programmes. Contributions from public entities based in these countries count toward their countries’ commitments to Global Health EDCTP3, while supporting specific projects rather than work programmes. As public authorities, beyond providing financial resources, these organisations often help promote policy and product uptake by participating in research consortia. 

41 other co-funders had provided more than €32 million to support projects. Of these, 29 (71%) are based in Africa and 12 (29%) in Europe.  A further €21 million has been pledged through project proposals still under review. 

Global Health EDCTP3 works closely with regulatory agencies, public health authorities, and other strategic partners to strengthen the enabling environment for conducting clinical research.  

Strategic partners share Global Health EDCTP3’s commitment to promoting excellent, open, impact-driven and collaborative research and innovation in global health. They bring unique expertise and legitimacy that amplify the impact and visibility of our work. Collaborations with these organisations may be formalised through memoranda of understanding or take other forms, such as regular exchanges, participation in advisory bodies and joint initiatives. 

Our strategic partners include: 

• World Health Organization (WHO), including the Regional Offices for Africa (WHO AFRO) and Europe (WHO/Europe) 
• WHO Special Programme for Research and Training in Tropical Diseases (TDR) 
• African Medicines Agency (AMA) 
• African Centres for Disease Control and Prevention (Africa CDC) 
• Federation of European Societies for Tropical Medicine and International Health (FESTMIH) 
• The Global Health Network (TGHN) 
• EU partnership on One Health and Antimicrobial Resistance (EUP OHAMR) 
• Others  

Global Health EDCTP3 is also represented alongside its strategic partners in multiple cross-funder platforms and initiatives that are aimed at ensuring coordination and alignment between research funders, such as the ESSENCE on Health Research initiative, where it is represented as co-chair of the Steering Committee; the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), where it is represented on the Board; the PDP Funders Group; the Heads of International Research Organisations (HIROs); and the International Development Research Funders Forum (IRDFF), among others. 

Additionally, Global Health EDCTP3 receives strategic advice from its Stakeholders Group on priorities and opportunities for collaboration.